Investigational Drug Details
| Drug ID: | D013 |
| Drug Name: | Aramchol |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB11860 |
| DrugBank Description: | Aramchol has been used in trials studying the treatment of HIV, Gallstones, Fatty Liver, Metabolic Syndrome, and Nonalcoholic Steatohepatitis, among others. |
| PubChem ID: | 18738120 |
| CasNo: | 246529-22-6 |
| Repositioning for NAFLD: | No |
| SMILES: | O[C@H]1[C@@H]2[C@@H]([C@@]3([C@H](C1)C[C@H](CC3)NC(=O)CCCCCCCCCCCCCCCCCCC)C)C[C@@H]([C@]1([C@H]2CC[C@@H]1[C@@H](CCC(=O)O)C)C)O |
| Structure: |
|
| InChiKey: | SHKXZIQNFMOPBS-OOMQYRRCSA-N |
| Molecular Weight: | 702.118 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | SCD-1 |
| Therapeutic Category: | Enhance lipid metabolism |
| Clinical Trial Progress: | Phase 3 on-going (NCT04104321) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0051 | NCT02684591 | Phase 2 | Completed | Has Results | January 2016 | July 17, 2020 | Details |
| L0151 | NCT01094158 | Phase 2 | Completed | No Results Available | November 2010 | January 31, 2012 | Details |
| L0276 | NCT04104321 | Phase 3 | Recruiting | No Results Available | September 23, 2019 | October 28, 2021 | Details |
| L0356 | NCT02279524 | Phase 2 | Completed | Has Results | April 29, 2015 | July 14, 2021 | Details |
| L0453 | EUCTR2019-002073-56-FR | Phase 4 | Authorised | No Results Available | 20/09/2019 | 1 February 2020 | Details |
| L0454 | EUCTR2019-002073-56-GB | Phase 3 | Authorised | No Results Available | 17/09/2019 | 11 March 2020 | Details |
| L0616 | EUCTR2014-003107-29-DE | Phase 2 | Not Recruiting | No Results Available | 28/01/2015 | 28 February 2019 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00356 | 35122619 | J Physiol Biochem | Blockage of NDUFB9-SCD1 pathway inhibits adipogenesis : Blockage of NDUFB9-SCD1 pathway inhibits adipogenesis. | Details |
| A01778 | 34621052 | Nat Med | Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. | Details |
| A01853 | 34588764 | Drug Des Devel Ther | Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. | Details |
| A03058 | 34151243 | JHEP Rep | Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. | Details |
| A05080 | 33385317 | J Dig Dis | Efficacy and safety of drugs for nonalcoholic steatohepatitis. | Details |
| A05376 | 33278029 | Pharmacotherapy | Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | Details |
| A06162 | 32982112 | World J Gastroenterol | Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation. | Details |
| A08581 | 32052857 | Hepatology | New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. | Details |
| A08933 | 31931543 | Z Gastroenterol | [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?] | Details |
| A11166 | 31013363 | Hepatology | MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial). | Details |
| A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | Details |
| A14850 | 29204050 | World J Gastroenterol | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. | Details |
| A14950 | 29159325 | Hepatol Commun | Role of Aramchol in steatohepatitis and fibrosis in mice. | Details |
| A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | Details |
| A18671 | 27003143 | Dig Dis Sci | Novel Pharmacotherapy Options for NASH. | Details |
| A22109 | 24815326 | Clin Gastroenterol Hepatol | The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. | Details |
| A50136 | 35507280 | Curr Atheroscler Rep | Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. | Details |